Clinical bottom line
Low-dose naltrexone (LDN) is an emerging, putative therapeutic candidate for managing post-acute sequelae of SARS-CoV-2 infection (PASC), commonly known as Long COVID. Preliminary observational data and mechanistic rationale suggest LDN may modulate immune dysregulation and neuroinflammation implicated in PASC symptomatology. However, robust randomized controlled trial evidence remains lacking, and current findings warrant cautious interpretation. Primary care clinicians should consider LDN as an experimental adjunct in select patients with persistent PASC symptoms refractory to standard supportive care, pending further validation.
What the evidence shows
PASC encompasses a heterogeneous constellation of symptoms persisting beyond the acute phase of COVID-19, including fatigue, cognitive impairment, and autonomic dysfunction. Pathophysiological hypotheses emphasize persistent inflammation, immune dysregulation, and mitochondrial dysfunction (Newell et al., 2022; Ward et al., 2024). Low-dose naltrexone, an opioid receptor antagonist at doses typically 1–5 mg daily, is proposed to exert immunomodulatory effects by transiently blocking opioid receptors, thereby upregulating endogenous endorphins and modulating microglial activation.
Bonilla et al. (2023) conducted an observational study evaluating LDN in patients with PASC, reporting symptomatic improvement in fatigue and cognitive symptoms in a subset of participants. The study highlighted LDN’s potential to attenuate neuroinflammation, consistent with mechanistic insights from Ward et al. (2024) describing mitochondrial aberrations and microglial activation in PASC. These findings align with the broader understanding of immune persistence and antigen retention in PASC pathogenesis (Newell et al., 2022).
Mohammad et al. (2024) emphasize the role of metabolic dysregulation, including hyperglycemia, as a risk factor for cardiovascular complications post-PASC, underscoring the multifactorial nature of sequelae and the need for multimodal management strategies. While LDN’s direct impact on metabolic parameters remains uncharacterized, its immunomodulatory profile may indirectly influence systemic inflammation.
Caveats and uncertainty
The current evidence base for LDN in PASC is limited primarily to small observational cohorts without randomized controls or blinding, raising concerns about placebo effects and selection bias (Bonilla et al., 2023). Heterogeneity in PASC phenotypes and symptom duration complicates interpretation and generalizability. The optimal dosing regimen, treatment duration, and patient selection criteria for LDN remain undefined.
Mechanistic hypotheses, while biologically plausible, require further experimental validation in human subjects. Additionally, safety data specific to LDN in PASC populations are sparse, though LDN is generally well tolerated in other chronic conditions. Potential interactions with concurrent medications and long-term effects have not been systematically studied.
Given the evolving understanding of PASC and its multifactorial pathogenesis (Schulz et al., 2022), LDN should be viewed as an experimental adjunct rather than a standard therapy. Clinicians should remain vigilant for emerging evidence and integrate LDN use within a comprehensive, individualized care plan.
How this may change practice
Pending confirmatory clinical trials, LDN may become a low-cost, accessible option for symptom management in PASC patients with persistent neuroimmune symptoms unresponsive to conventional therapies. Primary care clinicians could consider discussing LDN as an off-label, adjunctive therapy after thorough patient counseling regarding the limited evidence and experimental nature.
Incorporation of LDN into PASC management protocols would necessitate monitoring for efficacy and adverse effects, ideally within research registries or pragmatic trials to build real-world evidence. Multidisciplinary collaboration including immunology, neurology, and rehabilitation specialists remains essential to address the complex needs of PASC patients.
Ultimately, LDN’s putative benefits must be balanced against uncertainties and the imperative to avoid delaying established supportive care measures. Clinicians should prioritize evidence-based symptom management and remain alert to new data that may clarify LDN’s role.